CapsoVision (CV) Competitors $4.00 +0.02 (+0.50%) As of 08/22/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsSEC FilingsTrendsBuy This Stock CV vs. AXGN, SIBN, BVS, ZIMV, AVNS, SMLR, KIDS, CBLL, TMCI, and DCTHShould you be buying CapsoVision stock or one of its competitors? The main competitors of CapsoVision include AxoGen (AXGN), SiBone (SIBN), Bioventus (BVS), ZimVie (ZIMV), AVANOS MEDICAL (AVNS), Semler Scientific (SMLR), OrthoPediatrics (KIDS), CeriBell (CBLL), Treace Medical Concepts (TMCI), and Delcath Systems (DCTH). These companies are all part of the "medical equipment" industry. CapsoVision vs. Its Competitors AxoGen SiBone Bioventus ZimVie AVANOS MEDICAL Semler Scientific OrthoPediatrics CeriBell Treace Medical Concepts Delcath Systems AxoGen (NASDAQ:AXGN) and CapsoVision (NASDAQ:CV) are both small-cap medical equipment companies, but which is the better business? We will compare the two companies based on the strength of their media sentiment, profitability, analyst recommendations, dividends, earnings, risk, valuation and institutional ownership. Does the media favor AXGN or CV? In the previous week, CapsoVision had 2 more articles in the media than AxoGen. MarketBeat recorded 6 mentions for CapsoVision and 4 mentions for AxoGen. AxoGen's average media sentiment score of 0.99 beat CapsoVision's score of -0.45 indicating that AxoGen is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment AxoGen 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive CapsoVision 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do analysts recommend AXGN or CV? AxoGen presently has a consensus target price of $26.00, suggesting a potential upside of 59.90%. CapsoVision has a consensus target price of $5.50, suggesting a potential upside of 37.50%. Given AxoGen's higher probable upside, research analysts clearly believe AxoGen is more favorable than CapsoVision.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score AxoGen 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00CapsoVision 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 3.50 Is AXGN or CV more profitable? CapsoVision has a net margin of 0.00% compared to AxoGen's net margin of -2.29%. CapsoVision's return on equity of 0.00% beat AxoGen's return on equity.Company Net Margins Return on Equity Return on Assets AxoGen-2.29% -4.43% -2.34% CapsoVision N/A N/A N/A Do insiders and institutionals hold more shares of AXGN or CV? 80.3% of AxoGen shares are held by institutional investors. 2.8% of AxoGen shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth. Which has better valuation & earnings, AXGN or CV? CapsoVision has lower revenue, but higher earnings than AxoGen. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAxoGen$187.34M3.99-$9.96M-$0.10-162.60CapsoVisionN/AN/AN/AN/AN/A SummaryAxoGen and CapsoVision tied by winning 6 of the 12 factors compared between the two stocks. Get CapsoVision News Delivered to You Automatically Sign up to receive the latest news and ratings for CV and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CV vs. The Competition Export to ExcelMetricCapsoVisionSurgical, Medical, And Dental Instruments And Supplies IndustryManufacturing SectorNASDAQ ExchangeMarket Cap$187.10M$172.87M$2.58B$9.76BDividend YieldN/AN/A2.54%4.06%P/E RatioN/A2.5522.0426.05Price / SalesN/A18.60282.1688.44Price / CashN/A4.2724.1559.36Price / BookN/A1.6031.916.60Net IncomeN/A-$66.04M$31.01M$265.65M7 Day Performance3.90%-2.22%1.08%2.00%1 Month Performance-6.32%-9.47%1.16%0.46%1 Year PerformanceN/A161.67%28.72%18.88% CapsoVision Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CVCapsoVisionN/A$4.00+0.5%$5.50+37.5%N/A$187.10MN/A0.0090AXGNAxoGen2.745 of 5 stars$14.93+0.2%$26.00+74.1%+29.9%$686.97M$187.34M-149.29450Short Interest ↑SIBNSiBone4.1616 of 5 stars$15.46+1.0%$23.67+53.1%-1.0%$666.96M$167.18M-27.61350News CoveragePositive NewsInsider TradeBVSBioventus0.9657 of 5 stars$7.37+0.4%N/AN/A$609.34M$573.28M14.741,200ZIMVZimVie0.673 of 5 stars$18.85+0.1%$17.75-5.8%+6.8%$531.59M$449.75M-26.931,770News CoverageShort Interest ↑AVNSAVANOS MEDICAL3.2831 of 5 stars$11.18+2.0%N/A-50.5%$519.70M$687.80M-1.112,227Positive NewsShort Interest ↑SMLRSemler Scientific3.4635 of 5 stars$33.84-3.7%$81.75+141.6%+7.1%$501.00M$42.98M13.93120KIDSOrthoPediatrics3.936 of 5 stars$19.19+0.3%$34.14+77.9%-38.0%$481.17M$204.73M-10.72200CBLLCeriBell2.3182 of 5 stars$12.31+4.4%$32.14+161.1%N/A$451.33M$65.44M-4.12N/ATMCITreace Medical Concepts2.606 of 5 stars$6.89-0.9%$9.83+42.7%+19.9%$435.26M$209.36M-8.72250DCTHDelcath Systems2.7896 of 5 stars$10.36-1.1%$24.50+136.5%+38.8%$362.40M$70.24M207.2060Short Interest ↑ Related Companies and Tools Related Companies AXGN Alternatives SIBN Alternatives BVS Alternatives ZIMV Alternatives AVNS Alternatives SMLR Alternatives KIDS Alternatives CBLL Alternatives TMCI Alternatives DCTH Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CV) was last updated on 8/24/2025 by MarketBeat.com Staff From Our PartnersGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredTrump’s betrayal exposedTrump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | Sponsored“Sell Nvidia before earnings”Eric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has bee...InvestorPlace | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | SponsoredTrump’s “new dollar” could shock Americans"I Made Millions in the Tech Boom. Here's Where I'd Put My Money Today" This man has called some of the big...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CapsoVision, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share CapsoVision With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access